Prophylaxis of Migraine, Transformed Migraine, and Cluster Headache with Topiramate

作者
Ninan T. Mathew,Jayasree Kailasam,Lori Meadors
出处
期刊:Headache [Wiley]
卷期号:42 (8): 796-803 被引量:89
标识
DOI:10.1046/j.1526-4610.2002.02183.x
摘要

OBJECTIVE: To assess the efficacy and tolerability of topiramate for prophylaxis of migraine and cluster headache via a retrospective chart analysis. BACKGROUND: Topiramate has multiple mechanisms of action that could potentially contribute to migraine prophylaxis. We conducted a retrospective chart review to assess the efficacy of topiramate as add-on therapy in patients with transformed migraine or cluster headache, and as first-line therapy in patients with episodic migraine. METHODS: Patients diagnosed with transformed migraine, episodic migraine, or cluster headache, who received topiramate either as add-on therapy or monotherapy were selected via retrospective chart review. Patients had begun topiramate therapy at 25 mg/day for the first week and increased their dosage by 25 mg/week to a maximum of 200 mg/day. Topiramate was used as add-on therapy for patients with transformed migraine and cluster headache, and as a first-line monotherapy in patients with episodic migraine who had no previous prophylactic therapy. The outcome parameters examined included a mean 28-day migraine frequency, migraine severity, number of headache days/month, number of abortive medication tablets/month, patient global evaluation, and the MIDAS scale. RESULTS: One hundred seventy-eight patients (transformed migraine: n = 96; episodic migraine: n = 70; and cluster headache: n = 12) were included in the retrospective analysis. The mean dose of topiramate for all patients was 87.5 mg/day. For patients with transformed migraine, mean migraine frequency decreased from 6.3/28 days to 3.7 (P = 0.005). Mean severity decreased from 7.1 to 3.8 on a 10-point scale, with 10 representing the most severe pain (P = 0.003). The mean number of headache days/month decreased from 22.1 to 9.6 (P = 0.001), and the mean number of abortive medication tablets decreased from 28.7/month to 10.6 (P = 0.001). Patient global evaluation indicated substantial or moderate improvement in 53% of patients with transformed migraine who used topiramate as add-on therapy. Mean MIDAS scale values decreased from 90.2 to 24.9 (P< 0.0001). The 70 episodic migraine patients who were administered topiramate as first-line therapy exhibited a decrease in mean migraine frequency (5.8/28 days to 1.9, P = 0.001), while mean migraine severity decreased from 8.1 to 2.0 (P = 0.003). Sixty-one percent of patients reported marked improvement. Nine of the 12 cluster headache patients exhibited substantial or moderate improvement in symptoms, whereas three had no improvement. The most common adverse effects were paresthesias (12%), cognitive effects (11%), and dizziness (6%). Eight patients discontinued topiramate due to adverse effects; cognitive effects were the most common reason. No patient discontinued topiramate treatment due to lack of efficacy. Twelve percent of patients lost more than 5 lbs during treatment (a range of 5-120 lbs). CONCLUSION: For both patients with transformed migraine (add-on therapy) and patients with episodic migraine (first-line monotherapy), topiramate yielded significant reductions in migraine frequency, migraine severity, number of headache days/month, and use of abortive medications. Topiramate also appears to be well tolerated and useful in the adjunctive treatment of cluster headache. Prospective double-blind, placebo-controlled trials will be required to confirm our results.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
有米饭没完成签到 ,获得积分10
刚刚
雨的印记完成签到 ,获得积分10
1秒前
跳跃猫咪完成签到 ,获得积分10
2秒前
Y_发布了新的文献求助20
2秒前
Emily完成签到,获得积分0
2秒前
咸鱼完成签到,获得积分10
2秒前
yunian完成签到 ,获得积分10
3秒前
lx完成签到,获得积分10
3秒前
大漂亮完成签到,获得积分10
3秒前
张思哲完成签到,获得积分10
3秒前
00001完成签到,获得积分10
4秒前
小蘑菇的应助被远方采纳,获得10
4秒前
4秒前
wanci的应助被刘猴采纳,获得10
4秒前
叶泽完成签到,获得积分10
4秒前
iOhyeye23完成签到 ,获得积分10
4秒前
许多多完成签到,获得积分10
5秒前
5秒前
郑成功完成签到,获得积分10
7秒前
7秒前
杰杰小杰发布了新的文献求助10
7秒前
wangyaofeng完成签到,获得积分10
7秒前
拿荷叶的火炬完成签到 ,获得积分10
7秒前
青木聪聪完成签到,获得积分10
8秒前
厄尔尼诺完成签到,获得积分10
8秒前
暴躁咩完成签到,获得积分10
8秒前
行悟完成签到 ,获得积分10
8秒前
文献狗完成签到,获得积分10
9秒前
kobee完成签到 ,获得积分10
9秒前
劳资懒得起网名完成签到,获得积分10
9秒前
火星上期待完成签到,获得积分20
9秒前
Akim的应助被于生有你采纳,获得10
9秒前
12完成签到 ,获得积分10
10秒前
李霞客完成签到,获得积分10
10秒前
知性的夏槐完成签到 ,获得积分10
10秒前
聚散流沙完成签到,获得积分10
11秒前
小马甲的应助被馨镜采纳,获得20
11秒前
senna发布了新的文献求助10
11秒前
碧蓝的灵安完成签到,获得积分10
11秒前
无私的犀牛完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180135
求助须知:如何正确求助?哪些是违规求助? 9570290
关于积分的说明 21809391
捐赠科研通 7776237
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557465
邀请新用户注册赠送积分活动 2479039